The 1999 domestic state of development of anti-asthma

K. Onodera, N. Sogawa, Chiharu Sogawa, H. Furuta

Research output: Contribution to journalArticle

Abstract

According to the "Guideline for Diagnosis and Treatment of Asthma" established by the Japanese Society of Allergy in 1998, inhaled adrenergic β2 agonists and inhaled corticosteroids are recommended for treatment of asthma. Thereafter, the development of new drugs for the treatment of asthma has begun changing. The concepts upon which the development of investigational drugs for asthma are based include improvements of drug delivery systems (ease of use, long-acting preparations, fewer side-effects), device design and appropriate auxiliary instrumentation. Moreover, chronic asthma has come to be recognized as an inflammatory disease of airway mucosa. At present, various antiallergic compounds such as tachykinin, leucotrien, PAF antagonists and others are under investigation thanks to the identification of new chemical mediators of airway inflammation and studies have progressed to the synthesis and manufacturing of new pharmaceuticals with antagonistic action. Thus, this review classified and introduced various new investigational anti-asthma and further describes the structure-activity relationships of β2 agonists and inhaled corticosteroids.

Original languageEnglish
Pages (from-to)385-394
Number of pages10
JournalFolia Pharmacologica Japonica
Volume116
Issue number6
Publication statusPublished - 2000

Fingerprint

Asthma
Adrenal Cortex Hormones
Investigational Drugs
Equipment Design
Leukotriene Antagonists
Tachykinins
Inflammation Mediators
Anti-Allergic Agents
Adrenergic Agonists
Drug Delivery Systems
Structure-Activity Relationship
Pharmaceutical Preparations
Hypersensitivity
Mucous Membrane
Therapeutics
Guidelines

Keywords

  • Anti-asthma
  • Asthma
  • Inhaled adrenergic β agonists
  • Inhaled corticosteroids
  • Investigational drugs for asthma

ASJC Scopus subject areas

  • Pharmacology

Cite this

Onodera, K., Sogawa, N., Sogawa, C., & Furuta, H. (2000). The 1999 domestic state of development of anti-asthma. Folia Pharmacologica Japonica, 116(6), 385-394.

The 1999 domestic state of development of anti-asthma. / Onodera, K.; Sogawa, N.; Sogawa, Chiharu; Furuta, H.

In: Folia Pharmacologica Japonica, Vol. 116, No. 6, 2000, p. 385-394.

Research output: Contribution to journalArticle

Onodera, K, Sogawa, N, Sogawa, C & Furuta, H 2000, 'The 1999 domestic state of development of anti-asthma', Folia Pharmacologica Japonica, vol. 116, no. 6, pp. 385-394.
Onodera, K. ; Sogawa, N. ; Sogawa, Chiharu ; Furuta, H. / The 1999 domestic state of development of anti-asthma. In: Folia Pharmacologica Japonica. 2000 ; Vol. 116, No. 6. pp. 385-394.
@article{d6a45bdc7dad47d29b19efd3223e4bf2,
title = "The 1999 domestic state of development of anti-asthma",
abstract = "According to the {"}Guideline for Diagnosis and Treatment of Asthma{"} established by the Japanese Society of Allergy in 1998, inhaled adrenergic β2 agonists and inhaled corticosteroids are recommended for treatment of asthma. Thereafter, the development of new drugs for the treatment of asthma has begun changing. The concepts upon which the development of investigational drugs for asthma are based include improvements of drug delivery systems (ease of use, long-acting preparations, fewer side-effects), device design and appropriate auxiliary instrumentation. Moreover, chronic asthma has come to be recognized as an inflammatory disease of airway mucosa. At present, various antiallergic compounds such as tachykinin, leucotrien, PAF antagonists and others are under investigation thanks to the identification of new chemical mediators of airway inflammation and studies have progressed to the synthesis and manufacturing of new pharmaceuticals with antagonistic action. Thus, this review classified and introduced various new investigational anti-asthma and further describes the structure-activity relationships of β2 agonists and inhaled corticosteroids.",
keywords = "Anti-asthma, Asthma, Inhaled adrenergic β agonists, Inhaled corticosteroids, Investigational drugs for asthma",
author = "K. Onodera and N. Sogawa and Chiharu Sogawa and H. Furuta",
year = "2000",
language = "English",
volume = "116",
pages = "385--394",
journal = "Folia Pharmacologica Japonica",
issn = "0015-5691",
publisher = "Japanese Pharmacological Society",
number = "6",

}

TY - JOUR

T1 - The 1999 domestic state of development of anti-asthma

AU - Onodera, K.

AU - Sogawa, N.

AU - Sogawa, Chiharu

AU - Furuta, H.

PY - 2000

Y1 - 2000

N2 - According to the "Guideline for Diagnosis and Treatment of Asthma" established by the Japanese Society of Allergy in 1998, inhaled adrenergic β2 agonists and inhaled corticosteroids are recommended for treatment of asthma. Thereafter, the development of new drugs for the treatment of asthma has begun changing. The concepts upon which the development of investigational drugs for asthma are based include improvements of drug delivery systems (ease of use, long-acting preparations, fewer side-effects), device design and appropriate auxiliary instrumentation. Moreover, chronic asthma has come to be recognized as an inflammatory disease of airway mucosa. At present, various antiallergic compounds such as tachykinin, leucotrien, PAF antagonists and others are under investigation thanks to the identification of new chemical mediators of airway inflammation and studies have progressed to the synthesis and manufacturing of new pharmaceuticals with antagonistic action. Thus, this review classified and introduced various new investigational anti-asthma and further describes the structure-activity relationships of β2 agonists and inhaled corticosteroids.

AB - According to the "Guideline for Diagnosis and Treatment of Asthma" established by the Japanese Society of Allergy in 1998, inhaled adrenergic β2 agonists and inhaled corticosteroids are recommended for treatment of asthma. Thereafter, the development of new drugs for the treatment of asthma has begun changing. The concepts upon which the development of investigational drugs for asthma are based include improvements of drug delivery systems (ease of use, long-acting preparations, fewer side-effects), device design and appropriate auxiliary instrumentation. Moreover, chronic asthma has come to be recognized as an inflammatory disease of airway mucosa. At present, various antiallergic compounds such as tachykinin, leucotrien, PAF antagonists and others are under investigation thanks to the identification of new chemical mediators of airway inflammation and studies have progressed to the synthesis and manufacturing of new pharmaceuticals with antagonistic action. Thus, this review classified and introduced various new investigational anti-asthma and further describes the structure-activity relationships of β2 agonists and inhaled corticosteroids.

KW - Anti-asthma

KW - Asthma

KW - Inhaled adrenergic β agonists

KW - Inhaled corticosteroids

KW - Investigational drugs for asthma

UR - http://www.scopus.com/inward/record.url?scp=0034529561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034529561&partnerID=8YFLogxK

M3 - Article

C2 - 11188507

AN - SCOPUS:0034529561

VL - 116

SP - 385

EP - 394

JO - Folia Pharmacologica Japonica

JF - Folia Pharmacologica Japonica

SN - 0015-5691

IS - 6

ER -